Early Access — free while we kick the tires
EdgarHawk

O'HEERON PETE

CHIEF EXECUTIVE OFFICER

Director Officer 10% Owner
4 filings analyzed · 2 companies · Latest 2026-03-04

Companies

Company Buys Sells Direction
FibroBiologics, Inc. FBLG 4 0 Net buying
LIBERTY STAR URANIUM & METALS CORP. LBSR 2 0 Net buying

Activity

March 2026
2026-03-04 FibroBiologics, Inc. FBLG
high
Buy
51,500 shares
$19,531
Significance 7/10

CEO Pete O'Heeron bought 51,500 shares (3 purchases) at blended $0.38 avg amid +32.4% 30-day rebound and cluster buy activity.

O'Heeron executed 3 separate purchases totaling 51,500 shares for $19,530.86 across March 2–4, 2026, at transaction prices ranging from $0.35 to $0.41. This adds 0.9% to his holdings of 5.96M shares post-transaction. The timing coincides with sharp price recovery: the stock has climbed 32.4% over 30 days and 44.4% over 90 days from depressed levels, currently trading at $7.51, -72.8% below its 52-week high of $27.60. Notably, 3 other insiders also bought within the past 14 days, forming a cluster buy pattern. However, the company remains unprofitable (net income $-5.8M), and O'Heeron's own cross-ticker track record shows modest timing accuracy (33.33% 90-day win rate on 9 prior buys, though his single prior FBLG purchase in August 2024 yielded extraordinary 90-day returns of +3787.2%). The CEO's accumulation during a recovery period, without fundamental improvement, warrants investor attention to whether this reflects conviction in turnaround prospects or a routine portfolio adjustment.

May 2025
Buy
3,190,718 shares
$236,751
Significance 4/10

O'HEERON PETE (COB, Secretary, Treasurer) bought 3,190,718 shares of LBSR at $0.07 for $236,751.28 on 2025-05-27.

O'HEERON PETE initiated a substantial position in LIBERTY STAR URANIUM & METALS CORP., acquiring 3,190,718 shares at $0.07 per share, representing his first material holding in the company since the transaction established 3,190,718 shares post-close. The stock currently trades at $0.08, reflecting modest near-term stability, though it remains 77.1% below its 52-week high of $0.35 and has declined 20.0% over both the 30-day and 90-day periods. Reviewing his same-ticker history at LBSR, O'HEERON has completed 5 prior purchases, with mixed outcomes: two transactions (2025-03-04 buy and 2023-10-12 buy) demonstrated positive 90-day returns of 7.7% and 843.4%, respectively, while three others (2023-08-29, 2023-08-11, 2023-08-11) delivered negative 90-day returns ranging from -41.3% to -94.3%. This filing's significance is modest given the company's fundamental profile—$0.00 revenue in the latest quarter, P/E of 0.89, and a $4.8M market cap—combined with mixed historical execution at the same ticker and a post-transaction stock price that has not recovered from recent declines.

March 2025
Buy
3,080,670 shares
$277,260
Significance 3/10

COB/Secretary/Treasurer O'Heeron Pete bought 3,080,670 shares of LBSR at $0.09 on 2025-03-04; stock at $0.10 current, down 84.4% from 52-week high.

O'Heeron Pete established a new position of 3,080,670 shares at $0.09 for a total value of $277,260.30 in a micro-cap uranium company trading 84.4% below its 52-week high of $0.64. His prior transactions at LBSR have yielded mixed results: 2 of 5 prior buys showed positive 90-day returns (including a +843.4% gain after an October 2023 purchase), but others delivered steep losses. The company reported zero revenue in the latest quarter and was unprofitable over its most recent full fiscal year, though it posted a single-quarter net income of $926,992.00. This purchase occurs after a -11.8% decline in the prior 30 days, positioning it at the lower end of the stock's recent trading range. The transaction reflects insider accumulation at depressed levels, but the company's negative full-year profitability and revenue shortfall suggest the fundamental outlook remains unclear.

August 2024
2024-08-12 FibroBiologics, Inc. FBLG
medium
Buy
8,500 shares
$16,269
Significance 4/10

CEO O'Heeron buys 8,500 shares of FBLG at $1.91 (Aug 12) amid -93.7% decline from 52-week high

CEO Pete O'Heeron purchased 8,500 shares at $1.91, bringing his total holdings to 6,056,647 shares. The buy occurred in a context of severe price deterioration: FBLG is down 93.7% from its 52-week high and has declined 61.4% over the preceding 30 days and 83.8% over 90 days. O'Heeron's cross-ticker track record shows 6 prior open-market buys with a 90-day average return of +136.7%, though the 33.33% win rate indicates significant variability in outcomes. The company reported a net loss for its most recent full fiscal year, though a recent quarter showed $898,000 in net income, creating mixed signals about profitability trajectory. This open-market purchase by the CEO deserves monitoring given the stock's sharp deterioration, but the modest share count increase (0.1% of pre-transaction holdings) and the insider's mixed historical returns limit the strength of any signal.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access